The Japan EP mapping and ablation device market will experience moderate growth through 2029, due to favorable reimbursement for ablation procedures, increasing AF ablation procedure volumes, and the uptake of premium-priced devices. However, the COVID-19 global pandemic will have a slight impact on the Japan EP mapping and ablation device market, resulting in lost procedure volumes in the short term followed by a period of recovery.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for EP mapping and ablation devices in Japan across a 10-year period.
The COVID-19 pandemic will affect the EP mapping and ablation device market in the short term.
How will COVID-19 affect procedure volumes?
What impact will the pandemic have on market dynamics?
How is the recovery of the procedure volumes expected to begin and proceed?
AF procedure volumes are the highest in Japan and continue to be the major focus among electrophysiologists.
How will the results of the CABANA, CASTLE-AF and the Pulsed AF trials affect AF procedure growth?
How fast are AF treatment volumes changing, and how does AF treatment volume growth compare to other arrhythmia types?
How are manufacturers incorporating novel technologies specifically for AF treatment into their competitive strategies?
The EP diagnostic and ablation catheter segments account for the major share of revenues.
How do the EP lab system and catheter markets compare?
What are the changing catheter preferences among electrophysiologists?
In which markets do competitors benefit most directly from growth trends?
A number of advance technologies are present in the Japanese market.
Which advanced technologies are available in the Japanese EP mapping and ablation device market?
Which of these novel devices have seen the fastest adoption, and why? How will their uptake change in the next 10 years?
Which devices are losing ground to these newer, more technologically advanced tools?
ASPs for EP devices are influenced by biennial reimbursement cuts by the Japanese MHLW.
Which device segments will be most affected by these cuts?
Are there specific brands that are exempt from these cuts? Why are they exempt?
- Electrophysiology Mapping And Ablation Devices - Market Insights - Japan
Author(s): Suraj Nair, Masters in Bioprocess Technology
Suraj Nair is a Research Associate within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in the Electrophysiology Mapping and Ablation Devices Market. Suraj holds a Master’s degree in Bioprocess Technology from the Institute of Chemical Technology, Mumbai and has a prior experience of working in the biopharmaceutical industry for two years and in the market research industry for medical devices for a year.